Recent studies have demonstrated that LILRB4 is expressed in microglia surrounding Aβ plaques in AD models, and that reducing LILRB4 expression through anti‐human LILRB4 monoclonal antibody (mAb) treatment decreases Aβ load and ameliorates some Aβ‐related behavioral abnormalities [14]. The gene discussed is LILRB4; the disease is Alzheimer disease.